Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance mechanisms render these inhibitors ineffective. Secondary oncogenic EGFR mutations account for approximately 50% of relapses, the most common being the gatekeeper T790M substitution that renders existing therapies ineffective. The discovery of PF-06459988 (1), an irreversible pyrrolopyrimidine inhibitor of EGFR T790M mutants, was recently disclosed.1 Herein, we describe our continued efforts to achieve potency across EGFR oncogenic mutations and improved kinome selectivity, resulting in the discovery of clinical candidate PF-06747775 (21), which provides potent EGFR activity against the four common mutants (exon 19 deletion (Del), L858R, and double mutants T790M/L858R and T790M/Del), selectivity over wild-type EGFR, and desirable ADME properties. Compound 21 is currently being evaluated in phase-I clinical trials of mutant EGFR driven NSCLC.

[1]  K. Houk,et al.  Transition states and energetics of nucleophilic additions of thiols to substituted α,β-unsaturated ketones: substituent effects involve enone stabilization, product branching, and solvation. , 2011, The Journal of organic chemistry.

[2]  Nathanael S Gray,et al.  Discovery of selective irreversible inhibitors for EGFR-T790M. , 2011, Bioorganic & medicinal chemistry letters.

[3]  Allard Kaptein,et al.  Irreversible protein kinase inhibitors: balancing the benefits and risks. , 2012, Journal of medicinal chemistry.

[4]  P. Harari,et al.  Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.

[5]  Peng Zhou,et al.  Fluorine Bonding - How Does It Work In Protein-Ligand Interactions? , 2009, J. Chem. Inf. Model..

[6]  Juswinder Singh,et al.  Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. , 2013, Cancer discovery.

[7]  Yoshikazu Ohta,et al.  Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. , 2013, ACS medicinal chemistry letters.

[8]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[9]  L. Hunter,et al.  The C–F bond as a conformational tool in organic and biological chemistry , 2010, Beilstein journal of organic chemistry.

[10]  David A. Price,et al.  Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks , 2010 .

[11]  R. V. van Montfort,et al.  Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach. , 2016, Journal of medicinal chemistry.

[12]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[13]  J. Renger,et al.  Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[14]  Gregory Riely,et al.  Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  Juswinder Singh,et al.  Targeted covalent drugs of the kinase family. , 2010, Current opinion in chemical biology.

[16]  Ke Ding,et al.  Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant. , 2012, Journal of medicinal chemistry.

[17]  A. Kalgutkar.  Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs. , 2014, Current medicinal chemistry.

[18]  R. W. Hoffmann,et al.  Is hyperconjugation responsible for the “gauche effect” in 1-fluoropropane and other 2-substituted-1-fluoroethanes?† , 1999 .

[19]  Benjamin F. Cravatt,et al.  A roadmap to evaluate the proteome-wide selectivity of covalent kinase inhibitors , 2014, Nature chemical biology.

[20]  R. Perez-soler.  The Role of Erlotinib (Tarceva, OSI 774) in the Treatment of Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[21]  J. A. Spicer,et al.  Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. , 2016, Journal of medicinal chemistry.

[22]  P. Kuzmič,et al.  Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance , 2013, Proceedings of the National Academy of Sciences.

[23]  Chun Xing Li,et al.  Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Ce , 2016, Journal of medicinal chemistry.

[24]  M. Meyerson,et al.  PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. , 2007, Cancer research.

[25]  K. Gajiwala,et al.  Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. , 2013, Structure.

[26]  Yu-Quan Wei,et al.  Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. , 2012, Journal of medicinal chemistry.

[27]  Li Di,et al.  Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.

[28]  Li Di,et al.  pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. , 2012, Molecular pharmaceutics.

[29]  J. Shih,et al.  The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer , 2011, Cancers.

[30]  Deepak Dalvie,et al.  Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. , 2016, Journal of medicinal chemistry.

[31]  Youngwook Kim,et al.  The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor , 2012, Molecular Cancer Therapeutics.

[32]  K. Scearce-Levie,et al.  Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. , 2014, Journal of medicinal chemistry.

[33]  Dafydd R Owen,et al.  Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis. , 2009, Bioorganic & medicinal chemistry letters.

[34]  Robert Mah,et al.  Drug discovery considerations in the development of covalent inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[35]  M. Eck,et al.  Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. , 2010, Biochimica et biophysica acta.

[36]  D. Eaton,et al.  Concise review of the glutathione S-transferases and their significance to toxicology. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[37]  Gary Gintant,et al.  An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. , 2011, Pharmacology & therapeutics.

[38]  A. Favaretto,et al.  Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. , 2011, Current drug targets.

[39]  David O'Hagan,et al.  Understanding organofluorine chemistry. An introduction to the C-F bond. , 2008, Chemical Society reviews.

[40]  Wei Liu,et al.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos , 2014, Journal of medicinal chemistry.

[41]  Peter Ballard,et al.  Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. , 2014, Journal of medicinal chemistry.

[42]  William Pao,et al.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.